GRHL2-HER3 and E-cadherin mediate EGFR-bypass drug resistance in lung cancer cells

GRHL2-HER3 and E-cadherin mediate EGFR-bypass drug resistance in lung cancer cells

Epidermal growth factor receptor (EGFR) is a major oncogenic protein, and thus EGFR-targeting therapies are widely used in patients with various types of cancer, including lung cancer. However, resistance to EGFR inhibitors, such as erlotinib, presents a significant challenge in treating lung cancer...

Full description

Saved in:
Bibliographic Details
Main Authors: Fumiya Ito, Wakiko Iwata, Yoshihiro Adachi, Hiromi Sesaki, Miho Iijima
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-01-01
Series:Frontiers in Cell and Developmental Biology
Subjects:
EGFR
lung cancer
drug resistance
GRHL2
HER3
cadherin
Online Access:https://www.frontiersin.org/articles/10.3389/fcell.2024.1511190/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items